Clinical trial
Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes
NCT00118287 · Fred Hutchinson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00118287 |
|---|---|
| Title | Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes |
| Official title | Therapy of Myelodysplastic Syndrome (MDS) With Azacitidine Given in Combination With Etanercept: A Phase I/II Study. |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes |
| Intervention type | Biological, Drug |
| Interventions | azacitidine, etanercept |
| Enrollment | 32 |
| Start date | Apr 1, 2005 |
| Primary completion | Oct 1, 2008 |
| First posted | Jul 11, 2005 |
| Last update posted | May 24, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: